Fact-checked by Grok 2 weeks ago

Janice Chen

Janice Chen is an biochemist and entrepreneur who co-founded Biosciences in 2017 and serves as its , leading the development of CRISPR-based technologies for diagnostics and therapeutics. During her Ph.D. research in the laboratory of Nobel laureate at the , Chen investigated CRISPR-Cas protein mechanisms and co-invented the DETECTR platform, a CRISPR-Cas12a-based system for rapid, programmable DNA detection that enables point-of-care diagnostics for diseases such as human papillomavirus and SARS-CoV-2. She earned a B.S. in Molecular and Cell Biology from in 2013 and a Ph.D. in Molecular and Cell Biology from UC Berkeley in 2018, where her dissertation focused on harnessing for diagnostic applications. At Mammoth Biosciences, headquartered in , Chen oversees the translation of these innovations into commercial products, including CRISPR-based gene editing technologies and the DETECTR assay, which was adapted for during the . Her contributions to diagnostics have earned her recognition as a 2019 honoree in Healthcare, as well as features in Technology Review's 35 Innovators Under 35 and Business Insider's 30 Under 40 in Healthcare. Chen has also delivered public talks on democratizing diagnostics through , including a 2018 TEDxCERN presentation, and holds multiple patents related to technologies.

Early life and education

Early life and family

Janice Chen was born and raised in , one of five siblings in a family of immigrants. Her parents, Zhidong Chen and Hetty Wang, emigrated from to the in 1988, with Zhidong hailing from the region. The family includes her sister , brothers Tony and Colin, and brother , an Olympic gold medalist in whose 2022 success highlighted the siblings' mutual support. Growing up in an immigrant household presented challenges, including cultural adjustment and economic pressures, yet her parents placed a strong emphasis on education and personal achievement to foster and opportunity for their children. excelled in extracurricular pursuits during her childhood, mastering the violin, competing in chess tournaments—often as the youngest and only female participant—and performing in dance. These activities reflected the family's encouragement of diverse talents amid their pursuit of excellence. Her early exposure to bioscience came through her father's ownership of a small biotech supply company in , where she assisted and developed an initial fascination with scientific innovation. This environment, combined with the immigrant ethos of perseverance, shaped her formative years and instilled a drive for intellectual and creative exploration.

Education

Chen received a B.S. in Molecular and Cellular Biology from . Chen then pursued graduate studies at the , where she earned a Ph.D. in Molecular and Cell Biology in 2018 under the supervision of in the Doudna Lab. During her doctoral training, her research centered on the mechanisms of CRISPR-Cas systems, building on her undergraduate foundation and bridging to advanced gene editing applications.

Scientific and professional career

Graduate research

Janice Chen conducted her PhD research in the laboratory of Jennifer Doudna at the University of California, Berkeley, from approximately 2014 to 2018, focusing on the mechanisms and applications of CRISPR-Cas systems for gene editing and molecular diagnostics. Her work centered on exploring the biochemical properties of diverse Cas enzymes to expand their utility beyond traditional genome editing, particularly in developing sensitive detection methods for nucleic acids. Under Doudna's mentorship, which guided the direction toward innovative CRISPR applications, Chen contributed to early efforts in characterizing these systems for rapid, point-of-care diagnostics. A pivotal discovery from Chen's graduate research was the identification of the collateral cleavage activity in Cas12a (previously known as Cpf1), an RNA-guided DNA endonuclease. In a 2018 study published in Science, Chen and colleagues demonstrated that upon binding and cleaving a target double-stranded DNA sequence, activated Cas12a indiscriminately degrades nearby single-stranded DNA, a property termed "collateral activity." This mechanism enables amplification-free detection of specific targets, forming the basis for CRISPR-based diagnostic platforms capable of identifying pathogens or genetic in clinical samples such as , , or . The finding laid the groundwork for the DETECTR (DNA endonuclease-targeted CRISPR trans reporter) system, a precursor technology for portable, low-cost molecular testing. During her , Chen co-authored several peer-reviewed publications on -Cas innovations, including investigations into specificity and engineering for enhanced targeting accuracy, such as a 2017 Nature paper on improved variants with reduced off-target effects. She also contributed to multiple patents assigned to the , covering mechanisms and nucleic acid detection methods, which have influenced subsequent biotechnological developments. These outputs underscored her role in advancing from a genome-editing tool to a versatile platform for diagnostics, emphasizing conceptual advancements in function over exhaustive experimental metrics.

Mammoth Biosciences

In 2017, Janice Chen co-founded Mammoth Biosciences in , initially operating from a San Francisco incubator, alongside , Lucas Harrington, and Nobel laureate , with an initial emphasis on developing -based diagnostic technologies. As (CTO), Chen has led the company's research and development efforts, overseeing the creation of platforms such as DETECTR, which enables rapid disease detection; a notable application was the DETECTR BOOST SARS-CoV-2 Reagent Kit, the first -based test to receive U.S. () for detection in January 2022. Under Chen's leadership, Mammoth Biosciences achieved significant milestones, including raising a total of $265 million in funding by 2022, highlighted by a $195 million round in that propelled the company's valuation to $1 billion with investments from entities like and individual backer . The company also secured key partnerships, such as multi-year collaborations with in 2022 and in , yielding approximately $100 million in contracts and grants since 2020 to advance applications in therapeutics. Mammoth Biosciences expanded into therapeutics by leveraging ultracompact systems for gene editing, presenting preclinical data in 2025 on candidates like MB-111—a single-dose for persistent chylomicronemia—at the European Society of Gene & Cell (ESGCT) 32nd Annual Congress, and on editing in non-human at the Society of Gene & Cell Therapy (ASGCT) 2025 Annual Meeting. In September 2025, the company entered a non-exclusive licensing partnership with VedaBio to enhance diagnostics, further supporting its technological portfolio. Staff numbers grew from 30 to over 130 by 2022, with continued scaling to support ongoing R&D expansion. Chen envisions Mammoth Biosciences evolving into a $100 billion independent entity, pioneering next-generation solutions for both diagnostics and to realize the full potential of genetic .

Awards and honors

Early recognitions

During her PhD at the , Janice Chen received the (NSF) Graduate Research Fellowship in 2014, which recognized her excellence in research focused on mechanisms. In 2019, Chen was named to the list in the Healthcare category, honoring her contributions to -based diagnostics developed during her graduate studies in Jennifer Doudna's lab. Early in her career, Chen gained media attention as a young innovator in gene editing, including a 2018 TEDxCERN talk titled "Could Democratize Diagnostics?" where she discussed the potential of for accessible disease detection.

Major awards

In 2020, Janice Chen received prominent recognition for her leadership in , particularly her role at Biosciences in developing CRISPR-based diagnostics amid the . She was named to Business Insider's 30 Under 40 list in Healthcare, celebrating her contributions to rapid gene-editing tools for disease detection. That same year, Chen was selected for Endpoints News' Top 20 Women in Biopharma, honoring her impact on innovative therapies and diagnostics in the industry. The following year, in 2021, Chen was awarded MIT Technology Review's 35 Innovators Under 35, spotlighting her advancements in technologies for accessible and precise diagnostic platforms. This accolade underscored her transition from academic research to in democratizing gene-editing applications. Chen has earned additional honors reflecting her influence in biotech entrepreneurship, including inclusion in Entrepreneur Magazine's 100 Women of Influence in 2022, which highlighted her pioneering work with Nobel laureate on diagnostics and Mammoth's growth during the pandemic. She also serves as Chair of the Committee at the American Society of Gene & (ASGCT), where she guides strategic discussions on emerging editing technologies and their therapeutic potential. In 2022, profiled Chen as a leading female founder in innovation, tying her recognition to Mammoth Biosciences' achievement of status after raising $195 million in funding, which propelled the company's expansion in gene-editing therapeutics.

Personal life

Family

Janice Chen shares a close-knit relationship with her parents, Zhidong Chen, a research scientist, and Hetty Chen, a medical translator, both of whom immigrated from and instilled a strong emphasis on perseverance and education in their children. As one of five siblings, Chen maintains supportive bonds with her sisters Alice and brothers Tony, Colin, and Nathan, the youngest, whose gold medal win in figure skating at the 2022 Winter Olympics served as a profound family highlight. The family sustains strong extended ties between their roots in Utah, where the Chens raised their children, and California, where Janice Chen resides and pursues her professional endeavors. There are no public details available regarding Chen's spouse or children.

Community involvement

Chen serves on the advisory board of the Life Sciences Entrepreneurship Center at UC Berkeley, where she has mentored early-stage biotech startups since October 2021. In this role, she provides guidance on innovation and commercialization in the life sciences sector, drawing on her expertise to support emerging entrepreneurs. Beyond her primary professional responsibilities, Chen chairs the Committee of the American Society of Gene & Cell Therapy (ASGCT), contributing to leadership and strategic direction for advancing gene editing technologies. This volunteer commitment underscores her dedication to fostering collaboration and progress in the field. Chen is actively involved in diversity, equity, and inclusion efforts within STEM, particularly highlighting the experiences of Asian and immigrant professionals in biotech. She has spoken on these topics at events such as CES 2021, emphasizing the need for role models, support, and acceptance to maximize potential in diverse backgrounds. Residing in the San Francisco Bay Area, she continues to engage with organizations promoting broader societal contributions in biotechnology.

References

  1. [1]
    About Us - Mammoth Biosciences
    As co-founder and Chief Technology Officer of Mammoth Biosciences, Janice leads the Applied program by implementing CRISPR-based DETECTR technology towards ...
  2. [2]
    Janice Chen, Co-founder & CTO, Mammoth Biosciences
    Mar 16, 2021 · ... Education: BS, Molecular and Cell Biology, Johns Hopkins University; PhD, Molecular and Cellular Biology, University of California, Berkeley.Missing: background | Show results with:background
  3. [3]
    Mammoth Biosciences - Crunchbase Company Profile & Funding
    Mammoth Biosciences develops novel CRISPR applications for disease detection, research, agriculture, biodefense, and more. Founded. obfuscated. obfuscation.
  4. [4]
    CRISPR-Cas12a target binding unleashes indiscriminate single ...
    CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity. Janice S. Chen https://orcid.org/0000-0003-4797-3056, ...
  5. [5]
    CRISPR–Cas12-based detection of SARS-CoV-2 - Nature
    Apr 16, 2020 · The SARS-CoV-2 DETECTR assay is considered positive if there is detection of both the E and N genes or presumptive positive if there is ...
  6. [6]
    Janice Chen - VIB Training & Conferences
    Janice received her PhD from the lab of Nobel Laureate Professor Jennifer Doudna at University of California, Berkeley. She investigated mechanisms of CRISPR ...Missing: background | Show results with:background
  7. [7]
    'Riding a tiger' from lab to C-suite with Mammoth's Janice Chen
    May 16, 2023 · Chen was one of the main authors on a paper describing the DETECTR system to use CRISPR-CAS12 to detect the SARS-CoV-2 virus. After making ...
  8. [8]
    Janice Chen, 27; Trevor Martin, 29 - 2018-11-13 - 2019 30 Under 30
    Nov 13, 2018 · By The Numbers: Meet The Forbes 30 Under 30 Europe Class Of 2025 ... Lucas Herrington, 27; Janice Chen, 27; Trevor Martin, 29. Cofounders ...
  9. [9]
    Janice Chen, PhD - World Medical Innovation Forum
    Janice Chen is the co-founder and CTO of Mammoth Biosciences, a biotechnology company based in the San Francisco Bay Area that is harnessing the diversity ...
  10. [10]
    Janice Chen, PhD - Biocom California
    Janice Chen is the Co-founder and Chief Technology Officer at Mammoth Biosciences, a company she co-founded with Nobel Laureate Jennifer Doudna.<|separator|>
  11. [11]
    Janice Chen - AIChE
    Janice Chen is the co-founder and CTO of Mammoth Biosciences, a biotechnology company harnessing a revolutionary gene-editing tool called CRISPR.
  12. [12]
    Could CRISPR democratise diagnostics? | Janice Chen | TEDxCERN
    Dec 20, 2018 · ... Janice Chen, a recent PhD graduate in Molecular and Cell Biology from the University of California, Berkeley, has co-created DETECTR, a ...
  13. [13]
    30-year-old female founder's billion-dollar bet on CRISPR gene ...
    Mar 12, 2022 · Mammoth Biosciences is built on core technology Chen worked on at Doudna's UC Berkeley lab. Chen earned her PhD as a graduate student researcher ...
  14. [14]
    A mother's sacrifice, 'Rocket Man' and a little fun: How Nathan Chen ...
    Feb 9, 2022 · Hetty Wang met Zhidong Chen, a native of the Guangxi region in southwestern China, at a university in Beijing. He was a student of a friend of ...Missing: origin | Show results with:origin
  15. [15]
    Nathan Chen's Family: 5 Fast Facts You Need to Know - Heavy Sports
    Feb 8, 2018 · The decorated athlete has four older siblings, Alice, Janice, Tony and Colin, and he's got his older brothers to thank for his interest in skating.
  16. [16]
    Janice Chen - MIT Technology Review
    Jun 30, 2021 · At the time a PhD student at the University of California, Berkeley, Chen had been invited to a lab to look for the human papillomavirus in ...Missing: education background
  17. [17]
    Janice Chen - Mammoth Biosciences - LinkedIn
    Janice Chen is the co-founder and CTO of Mammoth Biosciences, a biotechnology company… · Experience: Mammoth Biosciences · Education: University of ...
  18. [18]
    Berkeley LSEC Advisory Board
    Janice Chen. Co-Founder and CTO, Mammoth Biosciences(link is external). PhD 2018, Jennifer Doudna Lab(link is external), UC Berkeley. Joe Jimenez. Co-Founder ...
  19. [19]
    People - Doudna Lab
    Assistant Professor of Biological Chemistry, Johns Hopkins University School of Medicine ... Janice Chen. 2015-2018. Co-founder, Mammoth Biosciences. Steven ...
  20. [20]
    CRISPR scissors, Cas12a, enables cutting-edge diagnostics
    Feb 15, 2018 · The new DETECTR system based on CRISPR-Cas12a can analyze cells, blood, saliva, urine and stool to detect genetic mutations, cancer and antibiotic resistance.<|control11|><|separator|>
  21. [21]
    Nobel laureate Doudna's biotech Mammoth hits over $1 bln in ...
    Sep 9, 2021 · Mammoth Biosciences, co-founded by Nobel laureate Jennifer Doudna, touched a valuation of more than $1 billion after raising $150 million in ...
  22. [22]
    Mammoth Biosciences Receives FDA Emergency Use Authorization ...
    Jan 24, 2022 · The DETECTR BOOST® SARS-CoV-2 Reagent Kit has not been FDA cleared or approved, but has been authorized for emergency use by FDA under an EUA ...
  23. [23]
    Mammoth Biosciences gets FDA EUA for CRISPR-based Covid-19 test
    Mammoth Biosciences co-founder and CTO Dr Janice Chen said: “Mammoth's DETECTR BOOST SARS-CoV-2 assay rivals best-in-class PCR performance and this ...
  24. [24]
    Bayer and Mammoth Biosciences to collaborate on novel gene ...
    Jan 10, 2022 · Under the terms of the agreement, Mammoth Biosciences will receive an upfront payment of USD 40 million and is eligible to receive target ...Missing: Vertex | Show results with:Vertex
  25. [25]
    Vertex and Mammoth Biosciences Announce Collaboration to ...
    Oct 26, 2021 · About the Collaboration. Under the terms of the agreement, Mammoth Biosciences will receive upfront payments of $41 million , including an ...Missing: Bayer grants 2020
  26. [26]
    Mammoth Biosciences to Present Preclinical Data on MB-111 at the ...
    Oct 1, 2025 · MB-111 is a potential first-in-class, single-dose in vivo CRISPR gene editing therapy for persistent chylomicronemia; Oral presentation ...
  27. [27]
    Mammoth Biosciences to Present Preclinical Data on In Vivo Gene ...
    May 1, 2025 · Mammoth Biosciences to Present Preclinical Data on In Vivo Gene Editing of Skeletal Muscle in Non-Human Primates with an Ultracompact CRISPR ...
  28. [28]
    VedaBio Expands CRISPR-Based Molecular Detection Platform ...
    Sep 9, 2025 · VedaBio Expands CRISPR-Based Molecular Detection Platform With Mammoth Biosciences' Technology. Published on. September 9, 2025.
  29. [29]
    30 Under 30 Spotlight: Unsung Heroes in Healthcare Janice Chen
    Dec 16, 2019 · 30 Under 30 Spotlight: Unsung Heroes in Healthcare Janice Chen | Forbes Healthcare Summit 2019. Video unavailable. Janice Chen, Co-Founder ...
  30. [30]
    Could CRISPR democratize diagnostics? | Janice Chen | TEDxCERN
    Dec 20, 2018 · In her young career, Janice Chen, a recent PhD graduate in ... DNA-detection technology based on the CRISPR gene-editing tool. The ...Missing: media | Show results with:media
  31. [31]
    30 Leaders Under 40 Changing Healthcare in 2020 - Business Insider
    Sep 30, 2020 · Janice Chen, 29, Lucas Harrington, 29, and Trevor Martin, 31, are using a gene-editing tool to create rapid coronavirus tests that can be taken ...
  32. [32]
    Janice Chen, Nathan Chen's sister, is building a $100 billion ...
    Mar 17, 2022 · Janice Chen, Ph.D., one of Olympic gold medalist Nathan Chen's siblings, is on a mission to build a $100 billion biotech company.Missing: parents | Show results with:parents<|control11|><|separator|>
  33. [33]
    100 Women of Influence in 2022 - Entrepreneur
    Oct 4, 2022 · Our annual celebration of the women leaders influencing their industries, defining our culture, and reimagining our future.
  34. [34]
    Committee Details - ASGCT
    Genome Editing Committee ; Janice Chen, PhD, Chair, Mammoth Biosciences ; Annarita Miccio, PhD, Member, Imagine Institute ; Jessica Chery, PhD, Member, Food and ...
  35. [35]
    Nathan Chen Parents: Who Is His Mother Hetty Wang ... - StyleCaster
    Feb 4, 2022 · His other sister, Janice Chen, graduated from the University of California, Berkeley, and is the co-founder of Mammoth Bioscience, a company ...
  36. [36]
    Figure Skater Nathan Chen's Whole Family Is Pretty Impressive
    Feb 4, 2022 · The couple emigrated to Salt Lake City, Utah the year before Nathan was born ... Janice Chen is very impressive. Nathan's sister Janice is just as ...
  37. [37]
    Who Are Nathan Chen's Siblings and Parents? Here Are the Details
    Feb 4, 2022 · His brothers are named Colin and Tony, and his sisters are named Alice and Janice. Alice spoke highly about her younger brother to Team USA, ...
  38. [38]
    ASGCT Members Lead Congressional Briefing on Gene Editing
    Janice Chen, PhD, Mammoth Biosciences; Matthew Porteus, MD, PhD, Standford University Medical School; Amy Raymond, PhD, Worldwide Clinical Trials. The ...Missing: Chair | Show results with:Chair
  39. [39]
    On Being Asian and Asian American in Tech - CES
    Mar 31, 2021 · Janice Chen, Co-Founder and CTO, Mammoth Biosciences. "As a first ... born in New York) to being almost de facto quieted by being unseen.